Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://doi.org/10.3322/caac.21387.CrossRefPubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. https://​doi.​org/​10.​3322/​caac.​21387.CrossRefPubMed

go back to reference Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5(1):29–33. https://doi.org/10.1097/JTO.0b013e3181c5920c.CrossRefPubMed Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5(1):29–33. https://​doi.​org/​10.​1097/​JTO.​0b013e3181c5920c​.CrossRefPubMed

go back to reference Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://doi.org/10.1016/S0025-6196(11)60735-0.CrossRefPubMed Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://​doi.​org/​10.​1016/​S0025-6196(11)60735-0.CrossRefPubMed

go back to reference Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774.CrossRefPubMed Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33. https://​doi.​org/​10.​1056/​NEJMoa1606774.CrossRefPubMed

go back to reference Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, Adamchuk G, Ahn MJ, Alexandru A, Altundag O, Alyasova A, Andrusenko O, Aoe K, Araujo A, Aren O, Arrieta Rodriguez O, Ativitavas T, Avendano O, Barata F, Barrios CH, Beato C, Bergstrom P, Betticher D, Bolotina L, Bondarenko I, Botha M, Buddu S, Caglevic C, Cardona A, Castro G Jr, Castro H, Cay Senler F, Cerny CAS, Cesas A, Chan GC, Chang J, Chen G, Chen X, Cheng S, Cheng Y, Cherciu N, Chiu CH, Cho BC, Cicenas S, Ciurescu D, Cohen G, Costa MA, Danchaivijitr P, de Angelis F, de Azevedo SJ, Dediu M, Deliverski T, de Marchi PRM, de The Bustamante Valles F, Ding Z, Doganov B, Dreosti L, Duarte R, Edusma-Dy R, Emelyanov S, Erman M, Fan Y, Fein L, Feng J, Fenton D, Fernandes G, Ferreira C, Franke FA, Freitas H, Fujisaka Y, Galindo H, Galvez C, Ganea D, Gil N, Girotto G, Goker E, Goksel T, Gomez Aubin G, Gomez Wolff L, Griph H, Gumus M, Hall J, Hart G, Havel L, He J, He Y, Hernandez Hernandez C, Hespanhol V, Hirashima T, Ho CMJ, Horiike A, Hosomi Y, Hotta K, Hou M, How SH, Hsia TC, Hu Y, Ichiki M, Imamura F, Ivashchuk O, Iwamoto Y, Jaal J, Jassem J, Jordaan C, Juergens RA, Kaen D, Kalinka-Warzocha E, Karaseva N, Karaszewska B, Kazarnowicz A, Kasahara K, Katakami N, Kato T, Kawaguchi T, Kim JH, Kishi K, Kolek V, Koleva M, Kolman P, Koubkova L, Kowalyszyn R, Kowalski D, Koynov K, Ksienski D, Kubota K, Kudaba I, Kurata T, Kuusk G, Kuzina L, Laczo I, Ladrera GEI, Laktionov K, Landers G, Lazarev S, Lerzo G, Lesniewski Kmak K, Li W, Liam CK, Lifirenko I, Lipatov O, Liu X, Liu Z, Lo SH, Lopes V, Lopez K, Lu S, Martinengo G, Mas L, Matrosova M, Micheva R, Milanova Z, Miron L, Mok T, Molina M, Murakami S, Nakahara Y, Nguyen TQ, Nishimura T, Ochsenbein A, Ohira T, Ohman R, Ong CK, Ostoros G, Ouyang X, Ovchinnikova E, Ozyilkan O, Petruzelka L, Pham XD, Picon P, Piko B, Poltoratsky A, Ponomarova O, Popelkova P, Purkalne G, Qin S, Ramlau R, Rappaport B, Rey F, Richardet E, Roubec J, Ruff P, Rusyn A, Saka H, Salas J, Sandoval M, Santos L, Sawa T, Seetalarom K, Seker M, Seki N, Seolwane F, Shepherd L, Shevnya S, Shimada AK, Shparyk Y, Sinielnikov I, Sirbu D, Smaletz O, Soares JPH, Sookprasert A, Speranza G, Srimuninnimit V, Sriuranpong V, Stara Z, Su WC, Sugawara S, Szpak W, Takahashi K, Takigawa N, Tanaka H, Tan Chun Bing J, Tang Q, Taranov P, Tejada H, Tho LM, Torii Y, Trukhyn D, Turdean M, Turna H, Ursol G, Vanasek J, Varela M, Vallejo M, Vera L, Victorino AP, Vlasek T, Vynnychenko I, Wang B, Wang J, Wang K, Wu Y, Yamada K, Yang CH, Yokoyama T, Yokoyama T, Yoshioka H, Yumuk F, Zambrano A, Zarba JJ, Zarubenkov O, Zemaitis M, Zhang L, Zhang L, Zhang X, Zhao J, Zhou C, Zhou J, Zhou Q, Zippelius A. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7.CrossRefPubMed Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, Adamchuk G, Ahn MJ, Alexandru A, Altundag O, Alyasova A, Andrusenko O, Aoe K, Araujo A, Aren O, Arrieta Rodriguez O, Ativitavas T, Avendano O, Barata F, Barrios CH, Beato C, Bergstrom P, Betticher D, Bolotina L, Bondarenko I, Botha M, Buddu S, Caglevic C, Cardona A, Castro G Jr, Castro H, Cay Senler F, Cerny CAS, Cesas A, Chan GC, Chang J, Chen G, Chen X, Cheng S, Cheng Y, Cherciu N, Chiu CH, Cho BC, Cicenas S, Ciurescu D, Cohen G, Costa MA, Danchaivijitr P, de Angelis F, de Azevedo SJ, Dediu M, Deliverski T, de Marchi PRM, de The Bustamante Valles F, Ding Z, Doganov B, Dreosti L, Duarte R, Edusma-Dy R, Emelyanov S, Erman M, Fan Y, Fein L, Feng J, Fenton D, Fernandes G, Ferreira C, Franke FA, Freitas H, Fujisaka Y, Galindo H, Galvez C, Ganea D, Gil N, Girotto G, Goker E, Goksel T, Gomez Aubin G, Gomez Wolff L, Griph H, Gumus M, Hall J, Hart G, Havel L, He J, He Y, Hernandez Hernandez C, Hespanhol V, Hirashima T, Ho CMJ, Horiike A, Hosomi Y, Hotta K, Hou M, How SH, Hsia TC, Hu Y, Ichiki M, Imamura F, Ivashchuk O, Iwamoto Y, Jaal J, Jassem J, Jordaan C, Juergens RA, Kaen D, Kalinka-Warzocha E, Karaseva N, Karaszewska B, Kazarnowicz A, Kasahara K, Katakami N, Kato T, Kawaguchi T, Kim JH, Kishi K, Kolek V, Koleva M, Kolman P, Koubkova L, Kowalyszyn R, Kowalski D, Koynov K, Ksienski D, Kubota K, Kudaba I, Kurata T, Kuusk G, Kuzina L, Laczo I, Ladrera GEI, Laktionov K, Landers G, Lazarev S, Lerzo G, Lesniewski Kmak K, Li W, Liam CK, Lifirenko I, Lipatov O, Liu X, Liu Z, Lo SH, Lopes V, Lopez K, Lu S, Martinengo G, Mas L, Matrosova M, Micheva R, Milanova Z, Miron L, Mok T, Molina M, Murakami S, Nakahara Y, Nguyen TQ, Nishimura T, Ochsenbein A, Ohira T, Ohman R, Ong CK, Ostoros G, Ouyang X, Ovchinnikova E, Ozyilkan O, Petruzelka L, Pham XD, Picon P, Piko B, Poltoratsky A, Ponomarova O, Popelkova P, Purkalne G, Qin S, Ramlau R, Rappaport B, Rey F, Richardet E, Roubec J, Ruff P, Rusyn A, Saka H, Salas J, Sandoval M, Santos L, Sawa T, Seetalarom K, Seker M, Seki N, Seolwane F, Shepherd L, Shevnya S, Shimada AK, Shparyk Y, Sinielnikov I, Sirbu D, Smaletz O, Soares JPH, Sookprasert A, Speranza G, Srimuninnimit V, Sriuranpong V, Stara Z, Su WC, Sugawara S, Szpak W, Takahashi K, Takigawa N, Tanaka H, Tan Chun Bing J, Tang Q, Taranov P, Tejada H, Tho LM, Torii Y, Trukhyn D, Turdean M, Turna H, Ursol G, Vanasek J, Varela M, Vallejo M, Vera L, Victorino AP, Vlasek T, Vynnychenko I, Wang B, Wang J, Wang K, Wu Y, Yamada K, Yang CH, Yokoyama T, Yokoyama T, Yoshioka H, Yumuk F, Zambrano A, Zarba JJ, Zarubenkov O, Zemaitis M, Zhang L, Zhang L, Zhang X, Zhao J, Zhou C, Zhou J, Zhou Q, Zippelius A. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30. https://​doi.​org/​10.​1016/​S0140-6736(18)32409-7.CrossRefPubMed

go back to reference Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39. https://doi.org/10.1056/NEJMoa1507643.CrossRefPubMedPubMedCentral Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39. https://​doi.​org/​10.​1056/​NEJMoa1507643.CrossRefPubMedPubMedCentral

go back to reference Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123–35. https://doi.org/10.1056/NEJMoa1504627.CrossRefPubMedPubMedCentral Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123–35. https://​doi.​org/​10.​1056/​NEJMoa1504627.CrossRefPubMedPubMedCentral

go back to reference Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://​doi.​org/​10.​1016/​S0140-6736(15)01281-7.CrossRefPubMed

go back to reference Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, de Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. https://doi.org/10.1016/S0140-6736(16)32517-X.CrossRefPubMed Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, de Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. https://​doi.​org/​10.​1016/​S0140-6736(16)32517-X.CrossRefPubMed

go back to reference Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33. https://doi.org/10.1200/JCO.2017.74.3062.CrossRefPubMedPubMedCentral Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung Cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33. https://​doi.​org/​10.​1200/​JCO.​2017.​74.​3062.CrossRefPubMedPubMedCentral

go back to reference Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. Clinical features and Management of Acquired Resistance to PD-1 Axis inhibitors in 26 patients with advanced non-small cell lung Cancer. J Thorac Oncol. 2018;13(6):831–9. https://doi.org/10.1016/j.jtho.2018.03.008.CrossRefPubMedPubMedCentral Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. Clinical features and Management of Acquired Resistance to PD-1 Axis inhibitors in 26 patients with advanced non-small cell lung Cancer. J Thorac Oncol. 2018;13(6):831–9. https://​doi.​org/​10.​1016/​j.​jtho.​2018.​03.​008.CrossRefPubMedPubMedCentral

go back to reference Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung Cancer. Oncologist. 2016;21(8):964–73. https://doi.org/10.1634/theoncologist.2015-0508.CrossRefPubMedPubMedCentral Campo M, Al-Halabi H, Khandekar M, Shaw AT, Sequist LV, Willers H. Integration of stereotactic body radiation therapy with tyrosine kinase inhibitors in stage IV oncogene-driven lung Cancer. Oncologist. 2016;21(8):964–73. https://​doi.​org/​10.​1634/​theoncologist.​2015-0508.CrossRefPubMedPubMedCentral

go back to reference Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer. 2017;106:50–7. https://doi.org/10.1016/j.lungcan.2017.02.007.CrossRefPubMed Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer. 2017;106:50–7. https://​doi.​org/​10.​1016/​j.​lungcan.​2017.​02.​007.CrossRefPubMed

go back to reference Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol (Toronto, Ont). 2019;26(1):e81–93.CrossRef Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr Oncol (Toronto, Ont). 2019;26(1):e81–93.CrossRef

go back to reference Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824–30. https://doi.org/10.1200/JCO.2014.56.7412.CrossRefPubMed Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32(34):3824–30. https://​doi.​org/​10.​1200/​JCO.​2014.​56.​7412.CrossRefPubMed

go back to reference Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8. https://doi.org/10.1016/j.ijrobp.2013.11.010.CrossRefPubMedPubMedCentral Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8. https://​doi.​org/​10.​1016/​j.​ijrobp.​2013.​11.​010.CrossRefPubMedPubMedCentral

go back to reference Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. https://doi.org/10.1097/JTO.0b013e3182745948.CrossRefPubMedPubMedCentral Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. https://​doi.​org/​10.​1097/​JTO.​0b013e3182745948​.CrossRefPubMedPubMedCentral

go back to reference Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV. Pattern of failure analysis in metastatic EGFR-mutant lung Cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10(11):1601–7. https://doi.org/10.1097/JTO.0000000000000648.CrossRefPubMed Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV. Pattern of failure analysis in metastatic EGFR-mutant lung Cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol. 2015;10(11):1601–7. https://​doi.​org/​10.​1097/​JTO.​0000000000000648​.CrossRefPubMed

go back to reference Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51. https://doi.org/10.1097/JTO.0b013e31827e1f83.CrossRefPubMedPubMedCentral Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(3):346–51. https://​doi.​org/​10.​1097/​JTO.​0b013e31827e1f83​.CrossRefPubMedPubMedCentral

go back to reference Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, Wang S, Hu M, Xu J, Lou Y, Dong Y, Niu Y, Yan B, Zhong R, Zhang W, Chu T, Zhong H, Han B. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies. Int J Cancer. 2020;146(11):3124–33. https://doi.org/10.1002/ijc.32717.CrossRefPubMed Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, Wang S, Hu M, Xu J, Lou Y, Dong Y, Niu Y, Yan B, Zhong R, Zhang W, Chu T, Zhong H, Han B. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies. Int J Cancer. 2020;146(11):3124–33. https://​doi.​org/​10.​1002/​ijc.​32717.CrossRefPubMed

go back to reference Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Suzuki H, Hirashima T, Atagi S, Imamura F. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One. 2018;13(2):e0192227. https://doi.org/10.1371/journal.pone.0192227.CrossRefPubMedPubMedCentral Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Suzuki H, Hirashima T, Atagi S, Imamura F. Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One. 2018;13(2):e0192227. https://​doi.​org/​10.​1371/​journal.​pone.​0192227.CrossRefPubMedPubMedCentral

go back to reference Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events with Nivolumab Efficacy in non–small-cell lung Cancer. JAMA Oncol. 2018;4(3):374–8. https://doi.org/10.1001/jamaoncol.2017.2925.CrossRefPubMed Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events with Nivolumab Efficacy in non–small-cell lung Cancer. JAMA Oncol. 2018;4(3):374–8. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​2925.CrossRefPubMed

go back to reference Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early immune-related adverse events and association with outcome in advanced non-small cell lung Cancer patients treated with Nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–805. https://doi.org/10.1016/j.jtho.2017.08.022.CrossRefPubMed Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early immune-related adverse events and association with outcome in advanced non-small cell lung Cancer patients treated with Nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–805. https://​doi.​org/​10.​1016/​j.​jtho.​2017.​08.​022.CrossRefPubMed

go back to reference Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung Cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2020;21(4):e315–28. https://doi.org/10.1016/j.cllc.2020.01.003.CrossRefPubMed Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung Cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2020;21(4):e315–28. https://​doi.​org/​10.​1016/​j.​cllc.​2020.​01.​003.CrossRefPubMed

go back to reference Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study. Lung Cancer. 2018;119:14–20. https://doi.org/10.1016/j.lungcan.2018.02.017.CrossRefPubMed Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study. Lung Cancer. 2018;119:14–20. https://​doi.​org/​10.​1016/​j.​lungcan.​2018.​02.​017.CrossRefPubMed

go back to reference Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, Maggiore RJ. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung Cancer. J Am Geriatr Soc. 2019;67(5):905–12. https://doi.org/10.1111/jgs.15750.CrossRefPubMedPubMedCentral Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, Maggiore RJ. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung Cancer. J Am Geriatr Soc. 2019;67(5):905–12. https://​doi.​org/​10.​1111/​jgs.​15750.CrossRefPubMedPubMedCentral

go back to reference Lichtenstein MRL, Nipp RD, Muzikansky A, Goodwin K, Anderson D, Newcomb RA, Gainor JF. Impact of age on outcomes with immunotherapy in patients with non-small cell lung Cancer. J Thorac Oncol. 2019;14(3):547–52. https://doi.org/10.1016/j.jtho.2018.11.011.CrossRefPubMed Lichtenstein MRL, Nipp RD, Muzikansky A, Goodwin K, Anderson D, Newcomb RA, Gainor JF. Impact of age on outcomes with immunotherapy in patients with non-small cell lung Cancer. J Thorac Oncol. 2019;14(3):547–52. https://​doi.​org/​10.​1016/​j.​jtho.​2018.​11.​011.CrossRefPubMed

go back to reference Landi L, D'Inca F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019;7(1):316. https://doi.org/10.1186/s40425-019-0793-8.CrossRefPubMedPubMedCentral Landi L, D'Inca F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019;7(1):316. https://​doi.​org/​10.​1186/​s40425-019-0793-8.CrossRefPubMedPubMedCentral

go back to reference Briceno O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. Aging Cell. 2016;15(1):14–21. https://doi.org/10.1111/acel.12384.CrossRefPubMed Briceno O, Lissina A, Wanke K, Afonso G, von Braun A, Ragon K, Miquel T, Gostick E, Papagno L, Stiasny K, et al. Reduced naive CD8(+) T-cell priming efficacy in elderly adults. Aging Cell. 2016;15(1):14–21. https://​doi.​org/​10.​1111/​acel.​12384.CrossRefPubMed

go back to reference Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, Jacobson LP, Multicenter ACS. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr. 2009;50(3):299–306. https://doi.org/10.1097/QAI.0b013e3181945eb0.CrossRefPubMedPubMedCentral Desquilbet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, Jacobson LP, Multicenter ACS. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr. 2009;50(3):299–306. https://​doi.​org/​10.​1097/​QAI.​0b013e3181945eb0​.CrossRefPubMedPubMedCentral

go back to reference Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911–27. https://doi.org/10.1128/JVI.77.8.4911-4927.2003.CrossRefPubMedPubMedCentral Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911–27. https://​doi.​org/​10.​1128/​JVI.​77.​8.​4911-4927.​2003.CrossRefPubMedPubMedCentral

go back to reference Victor CT-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7. https://doi.org/10.1038/nature14292.CrossRefPubMedCentral Victor CT-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7. https://​doi.​org/​10.​1038/​nature14292.CrossRefPubMedCentral

go back to reference Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514–26. https://doi.org/10.1158/1078-0432.CCR-16-1673.CrossRefPubMed Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514–26. https://​doi.​org/​10.​1158/​1078-0432.​CCR-16-1673.CrossRefPubMed

go back to reference Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung Cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276. https://doi.org/10.1001/jamaoncol.2019.1478.CrossRefPubMedPubMedCentral Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung Cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276. https://​doi.​org/​10.​1001/​jamaoncol.​2019.​1478.CrossRefPubMedPubMedCentral

go back to reference Campbell AM, Cai WL, Burkhardt D, Gettinger SN, Goldberg SB, Amodio M, Kaech S, Krishnaswamy S, Decker RH. Final results of a phase II prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent Pembrolizumab in patients with metastatic non-small cell lung Cancer (NSCLC). Int J Radiat Oncol. 2019;105(1):S36–7. https://doi.org/10.1016/j.ijrobp.2019.06.453.CrossRef Campbell AM, Cai WL, Burkhardt D, Gettinger SN, Goldberg SB, Amodio M, Kaech S, Krishnaswamy S, Decker RH. Final results of a phase II prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent Pembrolizumab in patients with metastatic non-small cell lung Cancer (NSCLC). Int J Radiat Oncol. 2019;105(1):S36–7. https://​doi.​org/​10.​1016/​j.​ijrobp.​2019.​06.​453.CrossRef

go back to reference Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to Cancer immunotherapy. Cell. 2017;168(4):707–23. https://doi.org/10.1016/j.cell.2017.01.017.CrossRefPubMedPubMedCentral Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to Cancer immunotherapy. Cell. 2017;168(4):707–23. https://​doi.​org/​10.​1016/​j.​cell.​2017.​01.​017.CrossRefPubMedPubMedCentral

go back to reference Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13–27. https://doi.org/10.1016/j.semcancer.2019.07.017.CrossRefPubMed Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: role of tumor-mediated immunosuppression. Semin Cancer Biol. 2020;65:13–27. https://​doi.​org/​10.​1016/​j.​semcancer.​2019.​07.​017.CrossRefPubMed

go back to reference Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer. 2020;19(1):141. https://doi.org/10.1186/s12943-020-01260-z.CrossRefPubMedPubMedCentral Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer. 2020;19(1):141. https://​doi.​org/​10.​1186/​s12943-020-01260-z.CrossRefPubMedPubMedCentral

go back to reference Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. Acquired resistance to PD-1/PD-L1 blockade in lung Cancer: mechanisms and patterns of failure. Cancers (Basel). 2020;12(12):3851. https://doi.org/10.3390/cancers12123851.CrossRef Pathak R, Pharaon RR, Mohanty A, Villaflor VM, Salgia R, Massarelli E. Acquired resistance to PD-1/PD-L1 blockade in lung Cancer: mechanisms and patterns of failure. Cancers (Basel). 2020;12(12):3851. https://​doi.​org/​10.​3390/​cancers12123851.CrossRef

go back to reference Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer discovery. 2017;7(3):264–76. https://doi.org/10.1158/2159-8290.CD-16-0828.CrossRefPubMed Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer discovery. 2017;7(3):264–76. https://​doi.​org/​10.​1158/​2159-8290.​CD-16-0828.CrossRefPubMed

go back to reference Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung Cancer. Cancer discovery. 2017;7(12):1420–35. https://doi.org/10.1158/2159-8290.CD-17-0593.CrossRefPubMedPubMedCentral Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung Cancer. Cancer discovery. 2017;7(12):1420–35. https://​doi.​org/​10.​1158/​2159-8290.​CD-17-0593.CrossRefPubMedPubMedCentral

go back to reference Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TNM, Lo RS, Ribas A. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29. https://doi.org/10.1056/NEJMoa1604958.CrossRefPubMedPubMedCentral Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TNM, Lo RS, Ribas A. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29. https://​doi.​org/​10.​1056/​NEJMoa1604958.CrossRefPubMedPubMedCentral

go back to reference George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, van Allen EM. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma. Immunity. 2017;46(2):197–204. https://doi.org/10.1016/j.immuni.2017.02.001.CrossRefPubMedPubMedCentral George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, van Allen EM. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma. Immunity. 2017;46(2):197–204. https://​doi.​org/​10.​1016/​j.​immuni.​2017.​02.​001.CrossRefPubMedPubMedCentral

go back to reference Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. https://doi.org/10.1038/ncomms10501.CrossRefPubMedPubMedCentral Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. https://​doi.​org/​10.​1038/​ncomms10501.CrossRefPubMedPubMedCentral

go back to reference Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561. https://doi.org/10.1080/2162402X.2016.1249561.CrossRefPubMed Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561. https://​doi.​org/​10.​1080/​2162402X.​2016.​1249561.CrossRefPubMed

go back to reference Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168–79. https://doi.org/10.1016/j.canlet.2019.05.003.CrossRefPubMed Saleh R, Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168–79. https://​doi.​org/​10.​1016/​j.​canlet.​2019.​05.​003.CrossRefPubMed

go back to reference Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front Immunol. 2020;11:783. https://doi.org/10.3389/fimmu.2020.00783.CrossRefPubMedPubMedCentral Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front Immunol. 2020;11:783. https://​doi.​org/​10.​3389/​fimmu.​2020.​00783.CrossRefPubMedPubMedCentral

go back to reference Hui R, Gandhi L, Costa EC, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl NB, Aggarwal C, Horn L, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol. 2016;34(15):9026. https://doi.org/10.1200/JCO.2016.34.15_suppl.9026.CrossRef Hui R, Gandhi L, Costa EC, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl NB, Aggarwal C, Horn L, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol. 2016;34(15):9026. https://​doi.​org/​10.​1200/​JCO.​2016.​34.​15_​suppl.​9026.CrossRef

go back to reference Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer. N Engl J Med. 2019;381(21):2020–31. https://doi.org/10.1056/NEJMoa1910231.CrossRefPubMed Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer. N Engl J Med. 2019;381(21):2020–31. https://​doi.​org/​10.​1056/​NEJMoa1910231.CrossRefPubMed